Turski ML - Search Results

1

A framework for genomic biomarker actionability and its use in clinical decision making.

Vidwans SJ, Turski ML, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R. Vidwans SJ, et al. Among authors: turski ml. Oncoscience. 2014 Oct 22;1(10):614-623. doi: 10.18632/oncoscience.90. eCollection 2014. Oncoscience. 2014. PMID: 25593991 Free PMC article.

2

Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm.

Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R. Turski ML, et al. Mol Cancer Ther. 2016 Apr;15(4):533-47. doi: 10.1158/1535-7163.MCT-15-0643. Epub 2016 Mar 23. Mol Cancer Ther. 2016. PMID: 27009213 Review.

3

Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome.

Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V; Pan-Cancer Working Group. Agarwal R, et al. Among authors: turski ml. Discov Med. 2014 Dec;18(101):323-30. Discov Med. 2014. PMID: 25549703 Free article. Review.

4

Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome.

Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V; Pan-Cancer Working Group. Agarwal R, et al. Among authors: turski ml. Discov Med. 2014 Dec;18(101):331-9. Discov Med. 2014. PMID: 25549704 Free article. Review.

5

Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies.

Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V; Pan-Cancer Working Group. Agarwal R, et al. Among authors: turski ml. Discov Med. 2015 Feb;19(103):101-8. Discov Med. 2015. PMID: 25725224 Free article. Review.

6

Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome.

Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V; Pan-Cancer Working Group. Agarwal R, et al. Among authors: turski ml. Discov Med. 2015 Feb;19(103):109-16. Discov Med. 2015. PMID: 25725225 Free article. Review.

7

Copper is required for oncogenic BRAF signalling and tumorigenesis.

Brady DC, Crowe MS, Turski ML, Hobbs GA, Yao X, Chaikuad A, Knapp S, Xiao K, Campbell SL, Thiele DJ, Counter CM. Brady DC, et al. Among authors: turski ml. Nature. 2014 May 22;509(7501):492-6. doi: 10.1038/nature13180. Epub 2014 Apr 9. Nature. 2014. PMID: 24717435 Free PMC article.

8

Ewing sarcoma in a child with neurofibromatosis type 1.

Fernandez KS, Turski ML, Shah AT, Bastian BC, Horvai A, Hardee S, Sweet-Cordero EA. Fernandez KS, et al. Among authors: turski ml. Cold Spring Harb Mol Case Stud. 2019 Oct 23;5(5):a004580. doi: 10.1101/mcs.a004580. Print 2019 Oct. Cold Spring Harb Mol Case Stud. 2019. PMID: 31645347 Free PMC article.

9

New roles for copper metabolism in cell proliferation, signaling, and disease.

Turski ML, Thiele DJ. Turski ML, et al. J Biol Chem. 2009 Jan 9;284(2):717-21. doi: 10.1074/jbc.R800055200. Epub 2008 Aug 29. J Biol Chem. 2009. PMID: 18757361 Free PMC article. Review. No abstract available.

10

A novel role for copper in Ras/mitogen-activated protein kinase signaling.

Turski ML, Brady DC, Kim HJ, Kim BE, Nose Y, Counter CM, Winge DR, Thiele DJ. Turski ML, et al. Mol Cell Biol. 2012 Apr;32(7):1284-95. doi: 10.1128/MCB.05722-11. Epub 2012 Jan 30. Mol Cell Biol. 2012. PMID: 22290441 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

18 results

Search Page